TH71270B - Methastin derivatives and their use - Google Patents

Abstract

DC60 (20/03/50) The invention provides a stable metastine derivative with excellent biological activity (cancer metastasis suppression activity, cancer growth suppression activity, gonadolescence stimulation activity, sex hormone stimulation activity, etc.). By replacing the amino acids of the metastine constituent with specific amino acids in the invented metastine derivative, blood stability, solubility, etc., were greatly improved; gel formation tendency was reduced; pharmacokinetics were also improved; and excellent cancer metastasis suppression or cancer growth suppression activity was demonstrated. In addition, the invented metastine derivative has gonadolescence suppression, sex hormone suppression, and other effects.

Claims (51)

Revised 15/8/2017 1. Selected metastain derivatives from: Ac-D-Tyr-Aze(2)-Asn-Thr-Phe-AzaGly-Leu-Arg(Me)-Trp-NH2 (compound no. 720), Ac-D-Tyr-Pic(2)-Asn-Thr-Phe-AzaGly-Leu-Arg(Me)-Trp-NH2 (compound no. 721), Ac-D-Tyr-Hyp-Asn-Thr-Phe-AzaGly-Leu-Arg(Me)-Trp-NH2 (compound no. 723), Ac-D-Tyr-Gly-Asn-Thr-Phe-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 726), Ac-D-Tyr-Aib-Asn-Thr-Phe-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 727), Ac-D-Tyr-D-NMeAla-Asn-Thr-Phe-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 732), Ac-D-Tyr-Izc-Asn-Thr-Phe-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 734), Ac-D-Tyr-D-Gln-Asn-Thr-Phe-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 738), Ac-D-Tyr-D-His-Asn-Thr-Phe-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound No. 739), Ac-D-Tyr-Ala-Asn-Thr-Phe-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound No. 742), Ac-D-Tyr-Ser-Asn-Thr-Phe-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound No. 744), Ac-D-Tyr-Lys-Asn-Thr-Phe-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound No. 745), Ac-D-Tyr-Glu-Asn-Thr-Phe-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound No. 746), Ac-D-Tyr-D-Trp-Asn-Thr-Phe(3F)-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 750), Ac-D-Tyr-Glu-Asn-Thr-Phe(2F)-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 755), Ac-D-Tyr-Lys-Asn-Thr-Phe(3F)-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 756), Ac-D-Tyr-Glu-Asn-Thr-Phe(3F)-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 757), Ac-D-Tyr-Lys-Asn-Thr-Phe(4C1)-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 758), Ac-D-Tyr-Glu-Asn-Thr-Phe(4C1)-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 759), Ac-D-Tyr-Hyp-Asn-Thr-Phe(2F)-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 763), Ac-D-Tyr-Hyp-Asn-Thr-Phe(3F)-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 765), Ac-D-Tyr-Hyp-Asn-Thr-Phe(4C1)-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 767), Ac-D-Tyr-His(3Me)-Asn-Thr-Phe-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 773), Ac-D-Tyr-Tyr(PO3H2)-Asn-Thr-Phe-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 775), Glycoloyl-D-Tyr-Hyp-Asn-Thr-Phe-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 776), Ac-D-Tyr-Hyp-Asn-Thr-Phe(4F)-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 787), Ac-D-Tyr-Glu-Asn-Thr-Phe(4F)-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 788), Ac-D-Tyr-Hyp-Asn-Thr-Phe-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 797), Ac-D-Tyr-Hyp-Asn-Ala-Thr-Phe-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 814), Ac-D-Tyr-Hyp-Asn-Thr-Phe-AzaGly-Ala(cPr)-Arg(Me)-Trp-NH2 (Compound 856), Ac-D-Tyr-Hyp-Asn-Thr-Phe(2Me)-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 870), Ac-D-Tyr-Hyp-Asn-Thr-Phe(3Me)-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 872), Ac-D-Tyr-Hyp-Asn-Thr-Phe(4Me)-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 874), Ac-D-Tyr-Hyp-Asn-Thr-threo-Ser(3phenyl)-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound No. 877), Ac-D-Tyr-Hyp-Asn-Thr-Erythro-Ser(3-phenyl)-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound No. 882), 3-(p-hydroxyphenyl)propionyl-Hyp-Asn-Thr-Phe-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound No. 888), Ac-D-Tyr-cisHyp-Asn-Thr-Phe-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound No. 896), Ac-D-Tyr-Pro(4F)-Asn-Thr-Phe-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound No. 897), or salts of these derivatives. ------------------------------------------------------------------------------------- (Original) 1. Metasatin derivatives represented by the formula: XX0-XX2-XX3-XX4-XX5-XX6-AzaGly-XX8-XX9-XX10-NH2 (where: XX0 represents formil, C1-20 alkanoyl, cyclopropane carbonyl, 6-(acetyl-D-arginil). (Amino)caproil,6-((R)-2,3-diaminopropionilamino)caproil,6-(D-norleucylamino)caproil,4-(D-arginylamino)butyryl,3-(4-hydroxyphenyl)propionil,glycil,tyrosil,acetylglycil,acetyltyrosil,D-tyrosil,acetyl-D-tyrosil,pyroglutamyl,3-(pyridin-3-yl)propionil,adipoil,glycoloyl,6-aminocaproil,6-acetylaminocaproil,4-[bis-(2-pyridylmethyl)aminomethyl]benzoil or 4-uridobenzoil; XX2 represents Tyr, D-Tyr, D-Ala, D-Leu, D-Phe, D-Lys, D-Trp or chemical bonds; XX3 represents: i) amino acids selected from Ala, Arg, Asn, Asp, Cys, Gln, Glu, Gly, His, Ile, Leu, Lys, Met, Phe, Ser, Thr, Tep, Tyr and Val, in which the (formula)-amino group may be methylated; ii) cyclic amino acids selected from Pro, Aze(2), Aze(3), Pic(2), Pic(3), Hyp, Thz, Abz(2), Abz(3), Pzc(2), Pro(4NH2), Hyp(Bzl), cisHyp, Pro(4F) and lzc; iii) amino acids selected from D-Dap,D-Pya(4),DL-Ala(Pip),Orn,Aib and Tyr(PO3H2); or, iv) chemical bonds; XX4 represents Asn,2-amino-3-uridopropionic acid,N(formula)-formyl-(formula)-diaminopropionic acid,N(formula)-acetyl-(formula)-diaminopropionic acid,N(formula)-pentyl asparagine,N(formula)-cyclopropyl asparagine,N(formula)-benzyl asparagine,2,4-diaminobutanic acid,2,3-diaminopropionic acid,His,Gln,Gly,Arg,Cit,Nva,D-Asn or chemical bonds; XX5 represents Ser, Thr, Val, NMeSer, Gly, Ala, Hyp, D-Ala, D-Thr, D-Pro or chemical bonds; XX6 represents Phe, Tyr, Trp, Tyr(Me), Thi, Nal(2), Cha, Pya(4), threo-Ser(3-phenyl), erythro-Ser(3-phenyl), or phenylalanine which may be selectively substituted; AzaGly represents azaglycine; XX8 represents Leu, Nva, Val or Ala(cPr); XX9 represents arginine which may be selectively substituted, lysine which may be selectively substituted or ornithine which may be selectively substituted; and XX10 represents 2-naphthyl alanine, 2-thienylalanine, tyrosine, phenylalanine which may be selectively substituted or tryptophan which may be selectively substituted); or salts of those substances. 2. Metasatin derivatives represented by the formula: XX0-XX2-XX3-XX4-XX5-XX6-AzaGly-XX8-XX9-XX10-NH2 (where: XX0 represents formil, C1-20 alkanoyl, cyclopropane carbonyl, 6-(acetyl-D-arginil). (Amino)caproil,6-((R)-2,3-diaminopropionilamino)caproil,6-(D-norleucylamino)caproil,4-(D-arginylamino)butyryl,3-(4-hydroxyphenyl)propionil,glycil,tyrosil,acetylglycil,acetyltyrosil,D-tyrosil,acetyl-D-tyrosil,pyroglutamyl,3-(pyridin-3-yl)propionil,adipoil,glycoloyl,6-aminocaproil,6-acetylaminocaproil,4-[bis-(2-pyridylmethyl)aminomethyl]benzoil or 4-uridobenzoil; XX2 represents Tyr, D-Tyr, D-Ala, D-Leu, D-Phe, D-Lys, D-Trp, or chemical bonds; XX3 represents D-Asp, D-Dap,D-Ser,D-Gln,D-His,D-Trp,D-Try,D-Pya(4), D-NMeAla, D-NMePhe,Aze(2),Aze(3),Pic(2),Pic(3),Hyp,Thz,Gly,Aib,Abz(2),Abz(3),Sar,Izc,Leu,Lys, Glu,Thr,Trp,Ser,Ala,NMeAla,(formula)-alanine,DL-Ala(Pip),Pzc(2),Orn,His(3Me),Tys(PO3H2), Pro(4NH2),Hyp(Bzl),cisHyp,Pro(4F) or chemical bonds; XX4 represents Asn,2-amino-3-uridopropionic Acid, N(formula)-formyl-(formula)-diaminopropionic acid, N(formula)-acetyl-(formula)-diaminopropionic acid, N(formula)-pentyl asparagine, N(formula)-cyclopropyl asparagine, N(formula)-benzyl asparagine, 2,4-diaminobutanic acid, 2,3-diaminopropionic acid, His, Gln, Gly, Arg, Ci, Nva, D-Asn or chemical bonds; XX5 represents Ser, Thr, Val, NMeSer, Gly, Ala, Hyp, D-Ala, D-Thr, D-Pro or chemical bonds; XX6 represents Phe, Tyr,Trp,Tyr(Me),Thi,Nal(2),Cha,Pya(4),Phe(2F),Phe(3F),Phe(4F), Phe(4CI),(formula)MePhe,Phe(2Me),Phe(3Me),Phe(4Me),threo-Ser(3phenyl),erythro-Ser(3phenyl) or D-Phe; AzaGly represents azaglycine; XX8 represents Leu,Nva,Val or Ala(cPr); XX9 represents Arg,Orm,Arg(Me),D-Arg or Arg(asymMe2); and, XX10 represents Phe,Trp,2-naphthyl alanine, 2-thienylalanine, tyrosine or 4-fluorophenylalanine); or salts of those substances. 3. Metasatin derivatives represented by the formula: XX0-XX2-XX3-XX4-XX5-XX6-AzaGly-XX8-XX9-XX10-NH2 (where: XX0 represents formil, C1-20 alkanoyl, cyclopropane carbonyl, 6-(acetyl-D-arginil). (Amino)caproil,6-((R)-2,3-diaminopropionylamino)caproil,6-(D-norleucylamino)caproil,4-(D-arginylamino)butyryl,3-(4-hydroxyphenyl)propionil,glycyl,tyrosyl,acetylglycyl,acetyltyrosyl,D-tyrosyl,acetyl-D-tyrosyl,pyroglutamyl,3-(pyridin-3-yl)propionil,adipoil,glycoloyl or 6-aminocaproil; XX2 represents Tyr,D-Tyr,D-Ala,D-Leu,D-Phe,D-Lys,D-Trp or chemical bonds; XX3 represents D-Asp, D-Dap,D-Ser,D-Gln,D-His,D-NMeAle, D-NMePhe,Aze(2),Pic(2), Pic(3),Hyp,Thz,NMeAla,Gly,Aib,Abz(2),Abz(3),Sar,Leu,Lys,Glu, (formula)-alanine,Pzc(2),Orn, His(3Me),Tyr(PO3H2),Pro(4NH2) or Hyp(Bzl); XX4 represents Asn,2-amino-3-uridopropionic acid,N(formula)-formyl-(formula)-diaminopropionic acid,N(formula)-acetyl-(formula)-diaminopropionic acid,N(formula)-pentyl asparagine,N(formula)-cyclopropyl Asparagine, N(formula)-benzyl asparagine, 2,4-diaminobutanic acid, His, Gln, Cit, or D-Asn; XX5 represents Ser, Thr, Val, NMeSer, Gly, Ala, Hyp, D-Ala or D-Thr; XX6 represents Phe, Tyr, Trp, Tyr(Me), Thi, Nal(2), Cha, Pya(4), Phe(2F), Phe(3F), Phe(4F), Phe(4CI) or D-Phe; AzaGly represents azaglycine; XX8 represents Leu, Nva or Val; XX9 represents Arg, Orn, Arg(Me) or Arg(asymMe2); And, XX10 represents Phe,Trp,2-naphthilalanine,2-thienylalanine,tyrosine, or 4-fluorophenylalanine); or salts of those substances. 4. Metasatin derivatives represented by the formula: XX0-XX2-XX3-XX4-XX5-XX6-AzaGly-XX8-XX9-XX10-NH2 (where: XX0 represents formil, C1-12 alkanoyl, cyclopropane carbonyl, 6-(acetyl-D-arginil). (Amino)caproil,6-((R)-2,3-diaminopropionylamino)caproil,6-(D-norleucylamino)caproil,4-(D-arginylamino)butyryl,3-(4-hydroxyphenyl)propionil,glycyl,tyrosyl,acetylglycyl,acetyltyrosyl,D-tyrosyl,acetyl-D-tyrosyl,pyroglutamyl,3-(pyridin-3-yl)propionil,adipoil,glycoloyl, or 6-aminocaproil; XX2 represents Tyr,D-Tyr,D-Ala,D-Leu,D-Phe,D-Lys,D-Trp or chemical bonds; XX3 represents D-Asp,D-Dap,D-Ser,D-Gln,D-His,D-NMeAle, D-NMePhe,Aze(2),Pic(2), Pic(3),Hyp,Thz,NMeAla,Gly,Aib,Abz(2),Abz(3),Sar,Leu,Lys,Glu, (formula)-alanine,Pzc(2),Orn, His(3Me),Tyr(PO3H2),Pro(4NH2) or Hyp(Bzl); XX4 represents Asn,2-amino-3-uridopropionic acid,N(formula)-formyl-diaminopropionic acid,N(formula)-acetyl-diaminopropionic acid,N(formula)-pentyl-asparagine,N(formula)-cyclopropyl Asparagine, N(formula)-benzyl asparagine or 2,4-diaminobutanic acid; XX5 represents Ser, Thr or Val; XX6 represents Phe, Tyr, Tip, Tyr(Me), Thi, Nal(2), Cha, Pya(4), Phe(2F), Phe(3F), Phe(4F) or Phe(4CI); AzaGly represents azaglycine; XX8 represents Leu, Nva or Val; XX9 represents Arg, Orn, Arg(Me) or Arg(asymMe2); and, XX10 represents Phe, Trp, 2-naphthylalanine, 2-thienylalanine, tyrosine or 4-fluorophenylalanine); or salts of those substances. 5. Derivatives of metastain or salts of those substances according to claim 1, where: XX0 represents C1-12 alkanoyl,6-aminocaproyl,6-acetylaminocaproyl, glycoyl,4-[bis-(2-pyridylmethyl)aminomethyl]benzoyl,4-uridobenzoyl,3-(4-hydroxyphenyl)propionyl or pyroglutamyl; XX2 represents D-Tyr, Tyr or chemical bond; XX3 represents D-Asp. D-Dap,D-Ser,D-Gln,D-His,D-Trp,D-Tyr,D-Pya(4)D-NMeAla, D-NMePhe,Aze(2),Aze(3),Pic(2),Pic(3),Hyp,Thz,Gly,Aib,Abz(2),Sar,lzc,Leu,Lys,Glu, Thr,Trp,Ser,Ala,NMeAla,(formula)-alanine,DL-Ala(Pip),Pzc(2),Orn,His(3Me),Tyr(PO3H2), Pro(4NH2),Hyp(Bzl),cisHyp,Pro(4F) or chemical bonds; XX4 represents Asn,2-amino-3-uridopropionic Acid, N(formula)-pentyl asparagine, N(formula)-cyclopropyl asparagine, N(formula)-benzyl asparagine, 2,4-diaminobutanolic acid, 2,3-diaminopropionic acid, His, Gln, Gly, Arg, Citr, Nva, D-Asn or chemical bonds; XX5 represents Thr, NMeSer, Gly, Ala, Hyp, D-Ala, D-Thr, D-Pro or chemical bonds; XX6 represents Phe,Phe(2F),Phe(3F),Phe(4F),Phe(4CI),(formula)MePhe,Phe(2Me),Phe(3Me), Phe(4Me),threo-Ser(3phenyl),erythro-Ser(3phenyl) or D-Phe; XX8 represents Leu or Ala(cPr); XX9 represents Arg,Arg(Me) or D-Arg and, XX10 represents Trp. 6. Derivatives of metastain according to claim 1, which are represented by the formula: XX0-XX2-XX3-XX4-XX5-XX6-AzaGly-XX8-XX9-XX10-NH2 (where: XX0 represents formil, C1-6 alkanoyl or glycolyl; XX2 represents D-Tyr or chemical bonds; XX3 represents Aze(2),Hyp,Gly,Aib,Leu,Lys,Glu,His(3Me),Tyr(PO3H2),Hyp(Bzl),cisHyp or Pro(4F); XX4 represents Asn or 2-amino-3-uridopropionic acid; XX5 represents Ser, Thr, or Ala; XX6 represents Phe, Cha, Phe(2F), Phe(3F), Phe(4F), Phe(4Cl), Phe(2Me), Phe(3Me), Phe(4Me), threo-Sre(3phenyl) or erythro-Ser(3phenyl); AzaGly represents azaglycine; XX8 represents Leu or Ala(cPr); XX9 represents Arg or Arg(Me); and, XX10 represents Phe or Trp); or salts of those substances. 7. Ac-D-Tyr-D-Trp-Asn-Thr-Phe-AzaGly-Leu-D-Arg-Trp-NH2 (Compound 708), Ac-Asn-Thr-Phe-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 709), Decanoyl-Asn-Thr-Phe-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 710), Acp-Asn-Thr-Phe-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 712), Ac-Acp-Asn-Thr-Phe-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 713), Ac-D-Tyr-D-Trp-Asp(NHPen)-Thr-Phe-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 714), Ac-D-Tyr-D-Trp-Asp(NHcPr)-Thr-Phe-AzaGly-Leu-Arg-(Me)-Trp-NH2 (Compound 715), Ac-D-Tyr-D-Trp-Asp(NHBzl)-Thr-Phe-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 716), Ac-D-Tyr-D-Trp-Alb-Thr-Phe-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound No. 717), Ac-D-Tyr-D-Pya(4)-Alb-Thr-Phe-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound No. 718), Ac-D-Tyr-D-Trp-Asn-D-Pro-Phe-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound No. 719), Ac-D-Tyr-Aze(2)-Asn-Thr-Phe-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound No. 720), Ac-D-Tyr-Pic(2)-Asn-Thr-Phe-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound No. 721), Ac-D-Tyr-Pic(3)-Asn-Thr-Phe-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound No. 722) Ac-D-Tyr-Hyp-Asn-Thr-Phe-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound No. 723), Ac-D-Tyr-Thz-Asn-Thr-Phe-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound No. 724), Ac-D-Tyr-NMeAla-Asn-Thr-Phe-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound No. 725) Ac-D-Tyr-Gly-Asn-Thr-Phe-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound No. 726) Ac-D-Tyr-Aib-Asn-Thr-Phe-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound No. 727), Ac-D-Tyr-Abz(2)-Asn-Thr-Phe-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound No. 728) Ac-D-Tyr-Aze(3)-Asn-Thr-Phe-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound No. 730) Ac-D-Tyr-Sar-Asn-Thr-Phe-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound No. 731) Ac-D-Tyr-D-NMeAla-Asn-Thr-Phe-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 732), Ac-D-Tyr-Izc-Asn-The-Phe-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 734), Ac-D-Tyr-Asp-Asn-Thr-Phe-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 735), Ac-D-Tyr-D-Dap-Asn-Thr-Phe-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 736), Ac-D-Tyr-D-Ser-Asn-Thr-Phe-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 737), Ac-D-Tyr-D-Gln-Asn-Thr-Phe-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 738), Ac-D-Tyr-D-His-Asn-Thr-Phe-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 739), Ac-D-Tyr-D-Trp-Dab-Thr-Phe-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 740), Ac-D-Tyr-Ala-Asn-Thr-Phe-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 742), Ac-D-Tyr-Leu-Asn-Thr-Phe-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 743), Ac-D-Tyr-Ser-Asn-Thr-Phe-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 744), Ac-D-Tyr-Lys-Asn-Thr-Phe-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 745), Ac-D-Tyr-Glu-Asn-Thr-Phe-AzaGly-Leu-D-Arg(Me)-Trp-NH2 (Compound 746), Ac-D-Tyr-(formula)-Ala-Asn-Thr-Phe-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 747), Ac-D-Tyr-D-Trp-Asn-Thr-Phe(4CI)-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 748), Ac-D-Tyr-D-Trp-Asn-Thr-Phe(2F)-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 749), Ac-D-Tyr-D-Trp-Asn-Thr-Phe(3F)-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 750), Ac-D-Tyr-Lys-Asn-Thr-Phe(2F)-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 754), Ac-D-Tyr-Glu-Asn-Thr-Phe(2F)-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 755), Ac-D-Tyr-Lys-Asn-Thr-Phe(3F)-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 756), Ac-D-Tyr-Glu-Asn-Thr-Phe(3F)-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 757), Ac-D-Tyr-Lys-Asn-Thr-Phe(4CI)-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 758), Ac-D-Tyr-Glu-Asn-Thr-Phe(4CI)-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound No. 759), Ac-D-Tyr-Pzc(2)-Asn-Thr-Phe-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound No. 760), Ac-D-Tyr-Hyp-Asn-Thr-Phe(2F)-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound No. 763), Ac-D-Tyr-Trp-Asn-Thr-Phe(2F)-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound No. 764), Ac-D-Tyr-Hyp-Asn-Thr-Phe(3F)-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 765), Ac-D-Tyr-Trp-Asn-Thr-Phe(3F)-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 766), Ac-D-Tyr-Hyp-Asn-Thr-Phe(4CI)-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 767), Ac-D-Tyr-Trp-Asn-Thr-Phe(4CI)-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 768), Ac-D-Tyr-Gly-Asn-Thr-Phe(4CI)-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 769), Ac-D-Tyr-Aib-Asn-Thr-Phe(4Cl)-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 770), Ac-D-Tyr-Orn-Asn-Thr-Phe-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 771), Ac-D-Tyr-Thr-Asn-Thr-Phe-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 772), Ac-D-Tyr-His(3Me)-Asn-Thr-Phe-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 773), Ac-D-Tyr-DL-Ala(Pip)-Asn-Thr-Phe-AzaGly-Leu-D-Arg(Me)-Trp-NH2 (Compound 774), Ac-D-Tyr-Tyr(PO3H2)-Asn-Thr-Phe-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 775), Glycoloyl-D-Tyr-Hyp-Asn-Thr-Phe-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 776) Ac-D-Tyr-Asn-Thr-Phe-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 777), Ac-D-Tyr-Pro(4NH2)-Asn-Thr-Phe-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 780), Ac-D-Tyr-Hyp(Bzl)-Asn-Thr-Phe-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 781), Ac-D-Tyr-D-NMePhe-Asn-Thr-Phe-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 782), Ac-D-Tyr-Gly-Asn-Thr-Phe(2F)-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 783), Ac-D-Tyr-Aib-Asn-Thr-Phe(2F)-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 784), Ac-D-Tyr-Gly-Asn-Thr-Phe(3F)-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 785), Ac-D-Tyr-Aib-Asn-Thr-Phe(3F)-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 786), Ac-D-Tyr-Hyp-Asn-Thr-Phe(4F)-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 787), Ac-D-Tyr-Glu-Asn-Thr-Phe(4F)-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 788), Ac-D-Tyr-Lys-Asn-Thr-Phe(4F)-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 789), Ac-D-Tyr-Gly-Asn-Thr-Phe(4F)-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 790), Ac-D-Tyr-Aib-Asn-Thr-Phe(4F)-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 791), Ac-D-Tyr-Hyp-Asn-Thr-D-Phe-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 794), Ac-D-Tyr-Hyp-Asn-Thr-Phe-AzaGly-Leu-Arg-Trp-NH2 (Compound 797), Ac-D-Tyr-Hyp-AIb-Thr-Phe-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 800), 4-[bis-(2-pyridylmethyl)aminomethyl]benzoyl-Phe-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 801), Ac-D-Tyr-Hyp-Asn-NMeSer-Phe-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 809), Ac-D-Tyr-Hyp-Asn-Hyp-Phe-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 810), Ac-D-Tyr-Hyp-Asn-Gly-Phe-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 813), Ac-D-Tyr-Hyp-Asn-Ala-Phe-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 814), Ac-D-Tyr-Hyp-Asn-D-Ala-Phe-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 815), Ac-D-Tyr-Hyp-His-Thr-Phe-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 816), Ac-D-Tyr-Hyp-Gln-Thr-Phe-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 843), Ac-D-Tyr-Hyp-D-Asn-Thr-Phe-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 844), Ac-D-Tyr-Hyp-Cit-Thr-Phe-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 845), Ac-D-Tyr-Hyp-Asn-D-Thr-Phe-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 846), Ac-D-Tyr-Hyp-Asn-Thr-Phe-AzaGly-Ala(cPr)-Arg(Me)-Trp-NH2 (Compound 856), 4-uridobenzoyl-Phe-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 860), Ac-D-Tyr-Hyp-Arg-Thr-Phe-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 861), Ac-D-Tyr-Hyp-Gly-Thr-Phe-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 862), Ac-D-Tyr-Hyp-Dap-Thr-Phe-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 863), Ac-D-Tyr-Hyp-Dab-Thr-Phe-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 864), Ac-D-Tyr-Hyp-Asn-Thr-(formula)MePhe-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 868), Ac-D-Tyr-Hyp-Asn-Thr-Phe(2Me)-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 870), Ac-D-Tyr-Hyp-Asn-Thr-Phe(3Me)-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 872), Ac-D-Tyr-Hyp-Asn-Thr-Phe(4Me)-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 874), Ac-D-Tyr-Hyp-Asn-Thr-threo-Ser(3phenyl)-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 877), Ac-D-Tyr-Hyp-Asn-Thr-erythro-Ser(3phenyl)-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 882), Ac-D-Tyr-Hyp-Nva-Thr-Phe-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 886), Ac-Hyp-Asn-Thr-Phe-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 887), 3-(p-hydroxyphenyl)propionyl-Hyp-Asn-Thr-Phe-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 888), pGlu-Asn-Thr-Phe-AzaGly-Len-Arg-(Me)-Try-NH2 (Compound 889), Ac-D-Tyr-cisHyp-Asn-Thr-Phe-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 896), Ac-D-Tyr-Pro(4F)-Asn-Thr-Phe-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 897), Ac-Tyr-Hyp-Asn-Thr-Phe-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 899), or salts of those compounds. 8. Ac-D-Tyr-D-Trp-Asp(NHPen)-Thr-Phe-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 714), Ac-D-Tyr-D-Trp-Asn(NHcPr)-Thr-Phe-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 715), Ac-D-Tyr-D-Trp-Asp(NHBzl)-Thr-Phe-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 716), Ac-D-Tyr-D-Trp-Alb-Thr-Phe-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound No. 717), Ac-D-Tyr-D-Pya(4)-Alb-Thr-Phe-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound No. 718), Ac-D-Tyr-Aze(2)-Asn-Thr-Phe-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound No. 720), Ac-D-Tyr-Pic(2)-Asn-Thr-Phe-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound No. 721), Ac-D-Tyr-Hyp-Asn-Thr-Phe-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 723), Ac-D-Tyr-Thz-Asn-Thr-Phe-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 724), Ac-D-Tyr-Gly-Asn-Thr-Phe-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 726), Ac-D-Tyr-Aib-Asn-Thr-Phe-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 727), Ac-D-Tyr-D-NMeAla-Asn-Thr-Phe-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 732), Ac-D-Tyr-D-Gln-Asn-Thr-Phe-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 738), Ac-D-Tyr-D-His-Asn-Thr-Phe-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 739), Ac-D-Tyr-D-Trp-Dab-Thr-Phe-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 740), Ac-D-Tyr-Ala-Asn-Thr-Phe-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 742), Ac-D-Tyr-Leu-Asn-Thr-Phe-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 743), Ac-D-Tyr-Ser-Asn-Thr-Phe-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 744), Ac-D-Tyr-Lys-Asn-Thr-Phe-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 745), Ac-D-Tyr-Glu-Asn-Thr-Phe-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 746), Ac-D-Tyr-D-Trp-Asn-Thr-Phe(4CI)-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 748), Ac-D-Tyr-D-Trp-Asn-Thr-Phe(2F)-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 749), Ac-D-Tyr-D-Trp-Asn-Thr-Phe(3F)-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 750), Ac-D-Tyr-Lys-Asn-Thr-Phe(2F)-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 754), Ac-D-Tyr-Glu-Asn-Thr-Phe(2F)-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 755), Ac-D-Tyr-Lys-Asn-Thr-Phe(3F)-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound No. 756), Ac-D-Tyr-Glu-Asn-Thr-Phe(3F)-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound No. 757), Ac-D-Tyr-Lys-Asn-Thr-Phe(4CI)-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound No. 758), Ac-D-Tyr-Glu-Asn-Thr-Phe(4CI)-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound No. 759), Ac-D-Tyr-Pzc(2)-Asn-Thr-Phe-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 760), Ac-D-Tyr-Hyp-Asn-Thr-Phe(2F)-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 763), Ac-D-Tyr-Trp-Asn-Thr-Phe(2F)-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 764), Ac-D-Tyr-Hyp-Asn-Thr-Phe(3F)-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 765), Ac-D-Tyr-Trp-Asn-Thr-Phe(3F)-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 766), Ac-D-Tyr-Hyp-Asn-Thr-Phe(4CI)-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 767), Ac-D-Tyr-Trp-Asn-Thr-Phe(4CI)-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 768), Ac-D-Tyr-Gly-Asn-Thr-Phe(4CI)-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 769), Ac-D-Tyr-Aib-Asn-Thr-Phe(4CI)-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 770), Ac-D-Tyr-Orn-Asn-Thr-Phe-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 771), Ac-D-Tyr-Thr-Asn-Thr-Phe-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 772), Ac-D-Tyr-His(3Me)-Asn-Thr-Phe-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 773), Ac-D-Tyr-Tyr(PO3H2)-Asn-Thr-Phe-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 775), Glycoloyl-D-Tyr-Hyp-Asn-Thr-Phe-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 776), Ac-D-Tyr-Pro(4NH2)-Asn-Thr-Phe-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 780), Ac-D-Tyr-Hyp(Bzl)-Asn-Thr-Phe-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 781), Ac-D-Tyr-D-NMePhe-Asn-Thr-Phe-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 782), Ac-D-Tyr-Gly-Asn-Thr-Phe(2F)-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 783), Ac-D-Tyr-Aib-Asn-Thr-Phe(2F)-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 784), Ac-D-Tyr-Gly-Asn-Thr-Phe(3F)-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 785), Ac-D-Tyr-Aib-Asn-Thr-Phe(3F)-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 786), Ac-D-Tyr-Hyp-Asn-Thr-Phe(4F)-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 787), Ac-D-Tyr-Glu-Asn-Thr-Phe(4F)-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 788), Ac-D-Tyr-Lys-Asn-Thr-Phe(4F)-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 789), Ac-D-Tyr-Gly-Asn-Thr-Phe(4F)-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 790), Ac-D-Tyr-Aib-Asn-Thr-Phe(4F)-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 791), Ac-D-Tyr-Hyp-Asn-Thr-D-Phe-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 794), Ac-D-Tyr-Hyp-Asn-Thr-Phe-AzaGly-Leu-Arg-Trp-NH2 (Compound 797), Ac-D-Tyr-Hyp-AIb-Thr-Phe-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 800), 4-[bis-(2-pyridylmethyl)aminomethyl]benzoyl-Phe-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 801), Ac-D-Tyr-Hyp-Asn-NMeSer-Phe-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 809), Ac-D-Tyr-Hyp-Asn-Hyp-Phe-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 810), Ac-D-Tyr-Hyp-Asn-Gly-Phe-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 813), Ac-D-Tyr-Hyp-Asn-Ala-Phe-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 814), Ac-D-Tyr-Hyp-Asn-D-Ala-Phe-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 815), Ac-D-Tyr-Hyp-His-Thr-Phe-AzaGly-Leu-D-Arg(Me)-Trp-NH2 (Compound 816), Ac-D-Tyr-Hyp-Gln-Thr-Phe-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 843), Ac-D-Tyr-Hyp-D-Asn-Thr-Phe-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 844), Ac-D-Tyr-Hyp-Cit-Thr-Phe-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 845), Ac-D-Tyr-Hyp-Asn-D-Thr-Phe-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 846), Ac-D-Tyr-Hyp-Asn-Thr-Phe-AzaGly-Ala(cPr)-Arg(Me)-Trp-NH2 (Compound 856), 4-uridobenzoyl-Phe-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 860), Ac-D-Tyr-Hyp-Arg-Thr-Phe-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 861), Ac-D-Tyr-Hyp-Gly-Thr-Phe-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 862), Ac-D-Tyr-Hyp-Dap-Thr-Phe-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 863), Ac-D-Tyr-Hyp-Dab-Thr-Phe-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 864), Ac-D-Tyr-Hyp-Asn-Thr-(formula)MePhe-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 868), Ac-D-Tyr-Hyp-Asn-Thr-Phe(2Me)-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 870), Ac-D-Tyr-Hyp-Asn-Thr-Phe(3Me)-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 872), Ac-D-Tyr-Hyp-Asn-Thr-Phe(4Me)AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 874), Ac-D-Tyr-Hyp-Asn-Thr-threo-Ser(3phenyl)-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 877), Ac-D-Tyr-Asn-Thr-erythro-Ser(3phenyl)-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 882), Ac-D-Tyr-Hyp-Nva-Thr-Phe-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 886), 3-(p-hydroxyphenyl)propionyl-Hyp-Asn-Thr-Phe-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 888), Ac-D-Tyr-cisHyp-Asn-Thr-Phe-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 896), Ac-D-Tyr-Pro(4F)-Asn-Thr-Phe-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 897), Ac-Tyr-Hyp-Asn-Thr-Phe-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 899), or salts of those compounds. 9. Ac-D-Tyr-Hyp-Asn-Thr-Phe-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 723), Ac-D-Tyr-Lys-Asn-Thr-Phe-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 745), Ac-D-Tyr-Glu-Asn-Thr-Phe-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 746), Ac-D-Tyr-Glu-Asn-Thr-Phe(3F)-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 757), Ac-D-Tyr-Hyp-Asn-Thr-Phe(3F)-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 765), Ac-D-Tyr-Hyp-Asn-Thr-Phe(4Cl)-AzaGly-Leu-D-Arg(Me)-Trp-NH2 (Compound 767), Ac-D-Tyr-Tyr(PO3H2)-Asn-Thr-Phe-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 775), Glycoloyl-D-Tyr-Hyp-Asn-Thr-Phe-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 776), Ac-D-Tyr-Hyp(Bzl)-Asn-Thr-Phe-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 781), Ac-D-Tyr-Hyp-Asn-Thr-Phe(4F)-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 787), or salts of those compounds. 10. Ac-D-Tyr-Hyp-Asn-Thr-Phe-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 723) or its salt. 11. Ac-D-Tyr-Lys-Asn-Thr-Phe-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 745) or its salt. 12. Ac-D-Tyr-Glu-Asn-Thr-Phe-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 746) or its salt. 13. Ac-D-Tyr-Glu-Asn-Thr-Phe(3F)-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 757) or a salt of those compounds. 14. Ac-D-Tyr-Hyp-Asn-Thr-Phe(3F)-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 765) or a salt of those compounds. 15. Ac-D-Tyr-Hyp-Asn-Thr-Phe(4CI)-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 767) or its salt. 16. Ac-D-Tyr-Tyr(PO3H2)-Asn-Thr-Phe-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 775) or a salt of those compounds. 17. Glycoloyl-D-Tyr-Hyp-Asn-Thr-Phe-AzaGly-Leu-Arg(Me)-Trp-NH2 (compound 776) or its salts. 18. Ac-D-Tyr-Hyp(Bzl)-Asn-Thr-Phe-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 781) or its salt. 19. Ac-D-Tyr-Hyp-Asn-Thr-Phe(4F)-AzaGly-Leu-Arg(Me)-Trp-NH2 (Compound 787) or a salt of those compounds. 20. Products of metastine derivatives as per claim 1 or salts of such substances. 21. Products of metastine derivatives as per claim 7 or salts of such substances. 22. Pharmaceutical products containing any of the metastin derivatives as specified in claims 1 through 19, or salts of those substances, or products of those substances. 23. Pharmaceutical products as per claim 22, which are substances for suppressing the metastasis of cancer or substances for suppressing the growth of cancer. 24. Pharmaceutical product as per claim 22, which is a substance for the prevention or treatment of cancer. 25. Pharmaceutical product as per claim 22, which is a substance for the regulation of placental function. 26. Pharmaceutical product according to claim 22, which is a substance for the prevention or treatment of choriocasinoma, molar pregnancy, cerebrovascular cancer, spontaneous abortion, fetal infertility, abnormal glucose metabolism, abnormal lipid metabolism or abnormal release induction. 27. Pharmaceutical product according to claim 22, which is a substance for improving the function of the gonads. 28. Pharmaceutical product as per claim 22, which is a substance for the prevention or treatment of hormone-dependent cancers, infertility, endometriosis, precocious puberty or uterine fibroids. 29. Pharmaceutical product according to claim 22, which is a substance for inducing or stimulating ovulation. 30. Pharmaceutical product according to claim 22, which is a sex hormone stimulant or sex hormone stimulant. 31. Pharmaceutical product as per claim 22, which is a substance for the prevention or treatment of Alzheimer's disease, autism or moderate cognitive impairment. 32. The use of any metastine derivatives under claims 1 through 19, or salts of such substances, or products of such substances in the manufacture of drugs for the suppression of cancer metastasis or cancer growth. 33. The use of any metastain derivatives under claims 1 through 19, or salts of such substances, or products of such substances in the manufacture of drugs for the prevention or treatment of cancer. 34. The use of any metastine derivatives under claims 1 through 19, or salts of such substances, or products of such substances in the manufacture of drugs for placental control. 35. The use of any of the metastain derivatives under claims 1 through 19, or their salts, or their products in the manufacture of drugs for the prevention or treatment of choriocasinoma, molar pregnancy, gestational trophoblastic cancer, spontaneous abortion, fetal infertility, abnormal glucose metabolism, abnormal lipid metabolism, or abnormal release induction. 36. The use of any of the metastine derivatives under claims 1 through 19, or their salts, or their products in the manufacture of drugs for improving gonadic function. 37. The use of any of the metastin derivatives under claims 1 through 19, or their salts, or their products in the manufacture of drugs for the prevention or treatment of hormone-dependent cancers, infertility, endometriosis, precocious puberty, or uterine fibroids. 38. Methods for inducing or stimulating ovulation, which include administering to mammals a dose that produces the effect of any of the metastin derivatives under claims 1 through 19, or salts of such, or products of such. 39. Methods for stimulating the secretion of sex hormones from the gonads, or stimulating the secretion of sex hormones, which include the administration of mammals a dose that produces the effect of any one of the metastin derivatives under claims 1 through 19, or salts of such substances, or products of such substances. 40. The use of any of the metastine derivatives under claims 1 through 19, or salts of such substances, or products of such substances in the manufacture of medicines for the prevention or treatment of Alzheimer's disease, autism or moderate cognitive impairment. 41. Pharmaceutical product according to claim 22, which is a substance that controls the activity of gonadic hormones or sex hormones. 42. The substance under claim 22, which is the inhibitory substance for the human OT7T175 (metastin receptor) protein, the amino acid sequence represented by SEQ ID NO: 9. 43. Pharmaceutical products as per claim 41 or 42, which are substances for the prevention or treatment of hormone-dependent cancer. 44. The use of any of the metastine derivatives under claims 1 through 19, or their salts, or their products in the manufacture of drugs for the control of gonadotropin or sex hormone activity. 45. The use of any metastin derivative under claims 1 through 19, or salts of such, or products of such in the manufacture of drugs for the control of human OT7T175 (metastin receptor) protein containing the amino acid sequence represented by SEQ ID NO: 9, to reduce its function. 46. The use of any of the metastine derivatives under claims 1 through 19, or salts of such substances, or products of such substances in the manufacture of drugs for the prevention or treatment of hormone-dependent cancers. 47. Methods for the prevention of cancer, which include the administration of to mammals the effective doses of any of the metastin derivatives under claims 1 through 19, or their salts, or their products. 48. Methods for the prevention of choriocasinoma, molar pregnancy, cerebrovascular cancer, spontaneous abortion, fetal infertility, abnormal glucose metabolism, abnormal lipid metabolism or abnormal release induction, which include administration of mammalian doses that produce the effect of any of the metastin derivatives under claims 1 through 19, or salts of such, or products of such. 49. Methods for the prevention of hormone-dependent cancers, infertility, endometriosis, precocious puberty or uterine fibroids, which include administration to mammals of doses that produce the effect of any one of the metastin derivatives as described in claims 1 through 19, or salts of such, or products of such. 50. A method for the prevention of Alzheimer's disease, autism, or moderate cognitive impairment, which includes the administration of mammals the drug doses of any one of the metastin derivatives under claims 1 through 19, or their salts, or their prodrugs. 51. Methods for the prevention of hormone-dependent cancers, which include the administration of any dose of the metastin derivatives as specified in claims 1 through 19, or their salts, or their products to mammals.